Disruption of RPGR protein interaction network is the common feature of RPGR missense variations that cause XLRP

Qihong Zhang^{a,1}, Joseph C. Giacalone^b, Charles Searby^a, Edwin M. Stone^{b,c}, Budd A. Tucker^{b,c}, and Val C. Sheffield^{a,b,c,1}

^aDepartment of Pediatrics, University of Iowa, Iowa City, IA 52242; ^bDepartment of Ophthalmology and Visual Sciences, University of Iowa Carver College of Medicine, Iowa City, IA 52242; and ^cInstitute for Vision Research, University of Iowa, Iowa City, IA 52242

Edited by Joseph C. Besharse, Medical College of Wisconsin, Milwaukee, WI, and accepted by Editorial Board Member Jeremy Nathans December 7, 2018 (received for review October 23, 2018)

Retinitis pigmentosa (RP) is an inherited retinal degenerative disease with severe vision impairment leading to blindness. About 10–15% of RP cases are caused by mutations in the *RPGR* gene, with *RPGR* mutations accounting for 70% of X-linked RP cases. The mechanism by which *RPGR* mutations cause photoreceptor cell dysfunction is not well understood. In this study, we show that the two isoforms of *RPGR* (*RPGR*^{1–19} and *RPGR*^{ORF15}) interact with endogenous PDE6D, INPP5E, and RPGRIP1L. The *RPGR*^{1–19} isoform contains two PDE6D binding sites with the C-terminal prenylation site being the predominant PDE6D binding site. The C terminus of *RPGR*^{1–19} that contains the prenylation site regulates its interaction with PDE6D, INPP5E, and RPGRIP1L. Only the *RPGR*^{1–19} isoform localizes to cilia in cultured RPE1 cells. Missense variations found in *RPGR* patients disrupt the interaction between *RPGR* isoforms and their endogenous interactors INPP5E, PDE6D, and RPGRIP1L. We evaluated a *RPGR* missense variation (M58K) found in a family with X-linked retinitis pigmentosa (XLRP) and show that this missense variation disrupts the interaction of *RPGR* isoforms with their endogenous interactors. The M58K variation also disrupts the ciliary localization of the *RPGR*^{1–19} isoform. Using this assay, we also show that some of the *RPGR* missense variants reported in the literature might not actually be disease causing. Our data establishes an *in vitro* assay that can be used to validate the potential pathogenicity of *RPGR* missense variants.

RPGR | cilia | retinal degeneration | PDE6D | INPP5E

Retinitis pigmentosa (RP) is an inherited retinal degenerative disease that results in the primary loss of rod photoreceptor cells followed by the secondary loss of cone photoreceptor cells (1). The disorder may be nonsyndromic occurring with retina dysfunction alone (1), or syndromic with other neurosensory disorders, developmental abnormalities, or complex clinical findings such as in Bardet-Biedl syndrome and Usher syndrome (2–4).

Mutations in any of dozens of different genes can cause the clinical phenotypes of retinitis pigmentosa, and these mutations can be inherited in an autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, mitochondrial, or digenic fashion (5–9). Approximately 15% of all RP is X-linked, and more than 80% of these patients (i.e., more than 12% of the total) have mutations in the gene *RPGR* (10). About 60% of all RP-causing mutations in *RPGR* occur in exon 15 of the gene, and two-thirds of these (more than 5% of all RP) occur in a highly repetitive region between codons 801 and 1070 (10).

There are multiple isoforms of *RPGR*. Two major isoforms of *RPGR* were detected in the retina (11, 12): *RPGR*^{1–19}, which has 19 exons encoding an 815-aa protein, and *RPGR*^{ORF15}, which has 15 exons plus part of intron 15 encoding a 1,152-aa protein. Both isoforms share exons 1–14. The N-terminal half of *RPGR* protein contains a tandem repeat structure highly similar to the regulator of chromosome condensation (RCC1) named RCC1-like domain (RLD), which regulates the RAN GTPase. The *RPGR*^{ORF15} protein has a Glu-Gly-rich low complexity re-

gion in the C-terminal domain. The C terminus of the *RPGR*^{1–19} protein contains a cluster of basic residues and a consensus prenylation site. Rescue experiments in *Rpgr* knockout mice demonstrate that the *RPGR*^{ORF15} isoform is functionally sufficient to rescue photoreceptor degeneration (13, 14).

RPGR localizes to connecting cilia of rod and cone photoreceptors, the transitional zone of motile cilia, and primary cilia both *in vivo* and *in vitro* (15–18). *RPGR* has been shown to be involved in microtubule organization or regulation of transport in primary cilia and actin stability (19–23). Likewise, *RPGR* is known to interact with numerous proteins including Whirlin (24), Gelsolin (20), SMC, IFT88, KIF3A, KAP3, NPM1, RAB8A, CEP290, RPGRIP1, RPGRIP1L, NPHP4, PDE6D, and INPP5E (17, 21, 22, 25–34). However, the importance of these interactions relative to the pathophysiology of *RPGR* is not known. Numerous mutations in *RPGR* associated with X-linked retinitis pigmentosa (XLRP) have been identified (35–41). These variants are found across the entire gene, with the majority of mutations occurring in the low complexity region of *RPGR*^{ORF15}. How these variants cause XLRP is not well understood. Here, we show that *RPGR* missense variations that cause XLRP disrupt the interaction of *RPGR* with its interactors and prevent ciliary localization of *RPGR*^{1–19}. Our study establishes a practical *in vitro* assay to evaluate *RPGR* missense variations in the RLD region in a cell culture system.

Significance

Due to its severity and early onset, X-linked retinitis pigmentosa (XLRP) is a particularly devastating form of retinal degeneration. Most males with XLRP come to medical attention before the age of 20. Approximately 15% of all RP is X-linked, and more than 70% of these cases are caused by mutations in the *RPGR* gene. Currently, there is no known assay to evaluate the nature of *RPGR* missense variants functionally. In this study, we developed an *in vitro* assay to examine how different missense variations in *RPGR* cause XLRP. Our assay is based on the *RPGR* protein interaction network. Our method provides a cost-effective test for *RPGR* functional mutation analysis.

Author contributions: Q.Z., E.M.S., B.A.T., and V.C.S. designed research; Q.Z., J.C.G., and C.S. performed research; Q.Z., J.C.G., C.S., and V.C.S. analyzed data; and Q.Z., E.M.S., B.A.T., and V.C.S. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. J.C.B. is a guest editor invited by the Editorial Board.

Published under the PNAS license.

¹To whom correspondence may be addressed. Email: qihong-zhang@uiowa.edu or val-sheffield@uiowa.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1817639116/-DCSupplemental.

Published online January 8, 2019.

Results

Both Isoforms of RPGR Interact with Endogenous PDE6D, INPP5E, and RPGRIP1L, but only RPGR¹⁻¹⁹ Localizes to Cilia. Two major RPGR isoforms are present in tissues and cells that arise through differential splicing (*SI Appendix, Fig. S1*): RPGR¹⁻¹⁹ and the retina-specific isoform RPGR^{ORF15} (11, 12). It has been shown that the RPGR¹⁻¹⁹ isoform interacts with PDE6D, INPP5E, and RPGRIP1L and localizes to primary cilia including connecting cilia of the retina (17, 27, 41). However, it is not known whether the RPGR^{ORF15} isoform also binds to these interactors. We first examined ciliary localization of RPGR^{ORF15} by transfecting GFP-tagged RPGR^{ORF15} into human retinal pigmented epithelial (RPE1) cells. In contrast to the RPGR¹⁻¹⁹ isoform (Fig. 1A–C), the RPGR^{ORF15} isoform (Fig. 1D–F) did not localize to cilia, instead, it was detected in the cytoplasm. Similar results were obtained in mouse IMCD3 cells (*SI Appendix, Fig. S2A–C*). To determine if the RPGR^{ORF15} can interact with endogenous PDE6D, INPP5E, and RPGRIP1L, we generated a Flag-S-tagged construct and expressed it in HEK293T cells. Using pulldown with anti-Flag beads, we show that RPGR^{ORF15} also interacts with endogenous PDE6D, INPP5E, and RPGRIP1L (Fig. 1K). Since both isoforms of RPGR share the RLD region (*SI Appendix, Fig. S3*), these data suggest that the binding domain for PDE6D, INPP5E, and RPGRIP1L resides in the RLD region. To test this, we generated a RPGR construct that contains the shared region of the two isoforms (RPGR-shared) and tested its interaction with PDE6D, INPP5E, and RPGRIP1L. The results demonstrate that the shared region of the two RPGR isoforms contain the binding domains for endogenous PDE6D, INPP5E, and RPGRIP1L (Fig. 1K). However, the shared region

cannot be targeted to primary cilia (Fig. 1G–I, also see *SI Appendix, Fig. S2C*).

The C-Terminal of the RPGR¹⁻¹⁹ Isoform That Contains the Prenylation Site Regulates Its Interaction with Endogenous PDE6D, INPP5E, and RPGRIP1L. The RPGR¹⁻¹⁹ isoform interacts with PDE6D much more strongly than the RPGR^{ORF15} isoform, indicating that the RPGR¹⁻¹⁹ isoform has additional binding sites for PDE6D. Altering the prenylation site of cysteine 812 to alanine (Fig. 2D–F) or deleting cysteine 812 (Fig. 2G–I) abolish RPGR¹⁻¹⁹ isoform ciliary localization, indicating that prenylation of cysteine 812 is required for RPGR¹⁻¹⁹ ciliary localization. Similar results were obtained in mouse IMCD3 cells (*SI Appendix, Fig. S2*). Changing the prenylation site of cysteine 812 to alanine or deleting cysteine 812 also greatly decreases but does not fully abolish RPGR¹⁻¹⁹ binding to PDE6D (Fig. 2K), indicating that the C-terminal of the RPGR¹⁻¹⁹ is the stronger binding site for PDE6D and that there is another binding site for PDE6D, likely in the RLD region. Interestingly, mutating the prenylation site of cysteine 812 to alanine or deleting cysteine 812 increases RPGR¹⁻¹⁹ isoform binding to endogenous INPP5E and RPGRIP1L (Fig. 2K). This finding suggests that prenylation of RPGR¹⁻¹⁹ modulates its protein structure, which in turn affects the RLD region of the protein, the binding region for INPP5E and RPGRIP1L, which leads to stronger binding of the RPGR¹⁻¹⁹ to INPP5E and RPGRIP1L.

The Ciliary Localization of RPGR¹⁻¹⁹ Is Regulated by PDE6D and RPGRIP1L, but Not by INPP5E. Although both isoforms of RPGR bind to endogenous PDE6D, INPP5E, and RPGRIP1L, only the RPGR¹⁻¹⁹ isoform localizes to primary cilia in cultured cells (Fig. 1, also see *SI Appendix, Fig. S2*), although the RPGR^{ORF15}

Fig. 1. Both isoforms of RPGR interact with endogenous PDE6D, INPP5E, and RPGRIP1L, but only RPGR¹⁻¹⁹ localizes to cilia. (A–I) GFP-tagged RPGR isoforms were transfected into RPE1 cells, the cells were stained with anti-GFP antibody to enhance and visualize GFP signal, and anti-polyglutamylated tubulin antibody GT335 was used as the cilia marker. Only GFP-tagged RPGR¹⁻¹⁹ isoform localizes to the primary cilia (A–C), while RPGR^{ORF15} isoform (D–F) and RPGR-shared region (G–I) do not localize to cilia. (J) Quantification of percentage of cells with GFP⁺ cilia in transfected RPE1 cells. (K) Flag-S-tag-conjugated RPGR isoforms were transfected into HEK293T cells and RPGR was pulled down by Flag beads. Western blots were used to detect endogenous RPGR interaction proteins using antibodies against PDE6D, RPGRIP1L, and INPP5E. RPGR¹⁻¹⁹ M58K and vector only transfected cells were used as negative controls. Detailed analysis of RPGR M58K variant can be found in Fig. 5. To avoid oversaturation of PDE6D by RPGR¹⁻¹⁹ IP, we loaded 15% of RPGR¹⁻¹⁹ IP at one end of the gel and 85% of RPGR¹⁻¹⁹ IP at another end of the gel. The anti-INPP5E antibody nonspecifically binds to the Precision Plus Protein Dual Color Standards from Bio-Rad at 75 kDa. Arrows indicate Flag-tagged RPGR isoforms. Each transfection was done three times. (Scale bar: 10 μ m.)

Fig. 2. Prenylation of the C terminus of RPGR¹⁻¹⁹ regulates its interaction with endogenous PDE6D, INPP5E, and RPGRIP1L. The C terminus of RPGR¹⁻¹⁹ contains a cysteine residue for prenylation. Mutation (D–F) or deletion (G–I) of the cysteine residue abolish the ability of the RPGR¹⁻¹⁹ isoform to localize to cilia compared with WT control (A–C). (J) Quantification of percentage of cells with GFP⁺ cilia in transfected RPE1 cells. (K) Disruption of RPGR prenylation affects its interaction with endogenous PDE6D, INPP5E, and RPGRIP1L. Flag-S-tag-conjugated WT and mutant RPGR¹⁻¹⁹ were transfected into HEK293T cells, and RPGR was pulled down by Flag beads. Western blots were used to detect RPGR¹⁻¹⁹ interaction proteins using antibodies against PDE6D, INPP5E, and RPGRIP1L. (L) The ratio of mutants to WT was calculated after quantifying each band using ImageJ and normalized to Flag and GAPDH. Each transfection was done three times. **P* < 0.05. (Scale bar: 10 μm.)

isoform was also shown to localize to connecting cilia in the mouse retina. To determine the importance of RPGR binding with PDE6D, INPP5E, and RPGRIP1L, mutations in all of which cause retinal degeneration, we knocked out *PDE6D*, *INPP5E*, and *RPGRIP1L* in RPE1 cells using the CRISPR-Cas9 genome editing system. We confirmed the knockout of these genes by direct sequencing, Western blotting, and/or immunofluorescent staining (Fig. 3 D and J' and SI Appendix, Fig. S4). While knockout of RPGRIP1L and PDE6D affect cilia number, knockout of RPGR and INPP5E do not have apparent effects on ciliogenesis (Fig. 3Q). It is known that PDE6D is required for the ciliary localization of prenylated proteins (42). In the absence of PDE6D, RPGR (Fig. 3 N–P) and INPP5E (Fig. 3 N'–P'), two proteins containing prenylation sites, cannot localize to cilia. In contrast to a previous report, our data indicate that RPGR is not required for INPP5E ciliary localization (Fig. 3 D'–F'). To confirm this result, we also used siRNA to knock down RPGR expression. Treating RPE1 cells with RPGR siRNA greatly decreases RPGR protein levels (SI Appendix, Fig. S5N) and effectively abolishes ciliary localization of RPGR (SI Appendix, Fig. S5 D–F). To rule out the possibility that there might be unknown RPGR isoforms that may not be targeted by the CRISPR guides, we treated RPGR knockout RPE1 cells or WT RPE1 cells with RPGR siRNA. siRNA against RPGR does not affect INPP5E ciliary localization (SI Appendix, Fig. S5 J–M). Similarly, loss of INPP5E does not affect ciliary localization of RPGR (Fig. 3 J–M). To further confirm these findings, we knocked down INPP5E expression using siRNA. Treating RPE1 cells with INPP5E siRNA effectively abolishes ciliary localization of INPP5E (SI Appendix, Fig. S6 D–F). However, knocking down INPP5E with siRNA does not affect RPGR ciliary localization (SI Appendix, Fig. S6 J–M). Of note, ciliary localization of RPGR and INPP5E do not absolutely require, but are regulated by,

RPGRIP1L (Fig. 3 R and S), suggesting that the integrity of the cilia transition zone regulates RPGR and INPP5E cilia localization. However, the transition zone localization of RPGRIP1L is not affected by loss of RPGR (SI Appendix, Fig. S7).

Most RP-Causing Missense Variations in the RLD Region Disrupt the Interaction Between RPGR Isoforms and Endogenous PDE6D, INPP5E, and RPGRIP1L. About 200 mutations in *RPGR* have been reported to cause XLRP. Most of them are deletions or insertions leading to premature stops in the low complexity region of the RPGR^{ORF15} isoform. Several RPGR missense variations have also been identified, the majority of which are located within the shared RLD region. These missense variants are rarely found in the gnomAD database (SI Appendix, Table S1). How these missense variations cause XLRP is not well understood. Since these variations locate to the RLD domain, a region that interacts with endogenous PDE6D, INPP5E, and RPGRIP1L, we hypothesized that these missense mutations disrupt the interaction of RPGR with these interactors. To test this hypothesis, we chose to evaluate G43R, F130C, G215V, and G275S variants, which are predicted to be damaging to RPGR protein function by Polyphen-2, SIFT, and Provean (SI Appendix, Tables S2–S4). To test if these variations affect RPGR¹⁻¹⁹ isoform ciliary localization, we transfected GFP-tagged WT and mutant RPGR¹⁻¹⁹ into RPE1 cells. In contrast to WT RPGR¹⁻¹⁹ (Fig. 4 A–C), mutant RPGR¹⁻¹⁹ (Fig. 4 D–O) cannot localize to the primary cilia. Similar results were obtained in mouse IMCD3 cells (SI Appendix, Fig. S2 F–I). To test if these variations affect the interaction between RPGR isoforms and their interactors, we transfected Flag-S-tag-tagged WT and mutant RPGR and RPGR-shared region into HEK293T cells and pulled down RPGR isoforms by Flag beads. Indeed, known mutations G43R, F130C, G215V, and G275S disrupt the

Fig. 3. Ciliary localization of the RPGR^{1–19} isoform is regulated by PDE6D and RPGRIP1L, but not by INPP5E. RPGR, INPP5E, PDE6D, and RPGRIP1L knockout RPE1 cells were generated by CRISPR-Cas9 and stained with RPGR (A–P) and INPP5E (A'–P') antibodies. All RPE1 knockout cell lines have normal cilia (stained by anti-polyglutamylated tubulin GT335) except for PDE6D and RPGRIP1L, which have fewer ciliated cells. PDE6D (N–P and N'–P') is required for ciliary localization of RPGR and INPP5E, while RPGRIP1L (G–I and G'–I') is not absolutely required for ciliary localization of RPGR and INPP5E, but regulate ciliary localization of RPGR and INPP5E compared with WT (A–C and A'–C'). Cilia localization of RPGR is not affected by loss of INPP5E (J–M) and ciliary localization of INPP5E is not affected by loss of RPGR (D'–F'). (Q) Quantification of cilia frequency in CRISPR knockout cells. (R) Quantification ciliary RPGR frequency in CRISPR knockout cells. (S) Quantification ciliary INPP5E frequency in CRISPR knockout cells. Three different clone lines for each gene knockout were analyzed. **P* < 0.05. (Scale bar: 10 μm.)

interaction between RPGR isoforms (RPGR^{1–19} and RPGR^{ORF15}) and their endogenous interactors PDE6D, INPP5E, and RPGRIP1L (Fig. 4 Q–S). Our data indicate that disruption of the RPGR protein network is probably a common feature for most RPGR missense variations in the RLD region that cause XLRP.

An RPGR M58K Variation Identified in a Family with XLRP Disrupts the Interaction of RPGR Isoforms with Their Interactors and Ciliary Localization of RPGR^{1–19} Isoform. We recently identified an M58K RPGR variation in a family with XLRP (10). The M58K variation is located in the first RCC1 domain of the RLD region (SI Appendix, Fig. S3) and is predicted to be damaging to RPGR protein function by Polyphen-2, SIFT, and Provean (SI Appendix, Tables S2–S4). To determine how this missense variation causes XLRP, we performed a pull-down assay as described above. The M58K variation disrupts the interaction between RPGR isoforms (RPGR^{1–19} and RPGR^{ORF15}) and their endogenous interactors PDE6D, INPP5E, and RPGRIP1L (Fig. 5 A–C). The M58K variation also disrupts ciliary localization of the RPGR^{1–19} isoform (Fig. 5 G–I). Analysis of skin fibroblast cells from

one of the patients with M58K variation confirms the lack of ciliary localization of mutant RPGR (Fig. 5 N–P). The M58K mutant RPGR protein level is also decreased (SI Appendix, Fig. S8), indicating the mutant RPGR protein is not stable. Skin fibroblast cells from the patient still have normal ciliary localization of INPP5E (SI Appendix, Fig. S9), consistent with data from CRISPR-Cas9 knockout RPE1 cells. Collectively, these data indicate that the M58K variation is the causative mutation in this XLRP family.

The RPGR Variation V36F That Causes Stationary Night Blindness Decreases the RPGR^{1–19} Isoform, but Not RPGR^{ORF15} Isoform, Interaction with Endogenous INPP5E. Three additional RPGR missense variations were investigated: G436D that causes XLRP, G566E that is likely a nondisease-causing polymorphism (36, 37, 40, 43, 44), and V36F that causes X-linked congenital stationary night blindness (CSNB) (44, 45). These variations locate outside of the RLD region (SI Appendix, Fig. S3). Polyphen-2, SIFT, and Provean analysis (SI Appendix, Tables S2–S4) indicates that the V36F mutation is predicted to be damaging, but to a lesser degree compared with other missense variations in the

Fig. 4. Most RP causing missense mutations in the RLD region disrupt the interaction between RPGR and PDE6D, INPP5E, and RPGRIP1L. GFP-tagged WT (A–C), G43R (D–F), F130C (G–I), G215V (J–L), and G275S (M–O) mutated RPGR^{1–19} transfected RPE1 cells show that these mutations disrupt the RPGR^{1–19} ciliary localization. (P) Quantification of percentage of cells with GFP⁺ cilia in transfected RPE1 cells. Flag-S-tag conjugated WT and mutant RPGR isoforms, and RPGR-shared region were transfected into HEK293T cells, and RPGR was pulled down by Flag beads. Western blots were used to detect RPGR interacting proteins. These mutations disrupt the interaction between the RPGR^{1–19} (Q), RPGR^{ORF15} (R), and RPGR-shared region (S) with endogenous PDE6D, INPP5E, and RPGRIP1L. Each transfection was done three times. (Scale bar: 10 μ m.)

RLD region. The G566E variation is predicted to be damaging by Polyphen-2 but are predicted to be likely benign by SIFT and Pro-vean, while the G436D variation is listed as benign (SI Appendix, Tables S2–S4). To determine the nature of these three missense variations, we first examined whether these missense variations affect RPGR^{1–19} isoform ciliary localization. None of the three variations affects RPGR^{1–19} ciliary localization (Fig. 6 D–L). Similar results were obtained in mouse IMCD3 cells (SI Appendix, Fig. S2 J–M). To determine if these missense variations affect the interaction between RPGR isoforms and their endogenous interactors PDE6D, INPP5E,

and RPGRIP1L, we performed pulldown assays. Of note, these missense variations do not fully disrupt the interaction between RPGR isoforms and their endogenous interactors PDE6D, INPP5E, and RPGRIP1L, unlike missense variations located in the RLD region (Fig. 6 N–P). Further analysis revealed that the V36F missense variation decreases the interaction of the RPGR^{1–19} isoform with INPP5E and RPGRIP1L, while the interaction between the RPGR^{ORF15} isoform with PDE6D, INPP5E, and RPGRIP1L is not affected (Fig. 6O). The decreased interaction of the RPGR V36F variant with PDE6D, INPP5E, and RPGRIP1L is more evident when using

Fig. 5. An M58K variation found in RP patients disrupts the interaction of RPGR with its interactors and ciliary localization of RPGR^{1–19}. Flag-S-tag-conjugated WT and mutant RPGR isoforms and RPGR-shared region were transfected into HEK293T cells, and RPGR was pulled down by Flag beads. Western blots were used to detect RPGR interacting proteins. M58K variation disrupts the interaction between RPGR^{1–19} (A), RPGR^{ORF15} (B), and RPGR-shared region (C) with endogenous PDE6D, INPP5E, and RPGRIP1L. GFP-tagged WT (D–F) and M58K (G–I) mutated RPGR^{1–19} transfected RPE1 cells show that M58K variation disrupts the RPGR^{1–19} ciliary localization. (J) Quantification of percentage of cells with GFP⁺ cilia in transfected RPE1 cells. Skin fibroblast cells from a patient with the M58K mutation lack RPGR cilia localization (N–P) compared with control skin fibroblast cells (K–M). (Q) Quantification of RPGR frequency of skin fibroblast cells. Each transfection was done three times. (Scale bars: 10 μ m.)

Due to its severity and early onset, XLRP is a particularly devastating form of retinal degeneration. Most males with XLRP come to medical attention before the age of 20. Approximately 15% of all RP is X-linked, and more than 70% of these cases are caused by mutations in the *RPGR* gene (10). There are estimated to be about 9,000 *RPGR*-associated RP patients in the United States, with just over 100 new cases identified each year (10). As the majority of *RPGR* mutations fall within the difficult-to-sequence low complexity

region of the gene, to accurately diagnose and treat the disease, it is important to develop a practical assay to accurately evaluate the pathogenicity of *RPGR* variants.

In this study, we developed an *in vitro* assay to examine how different missense variations in *RPGR* cause XLRP. Our assay is based on the *RPGR* protein interaction network. We demonstrated that XLRP causative missense mutations disrupt the interaction between *RPGR* isoforms and their endogenous interactors PDE6D, INPP5E, and RPGRIP1L. Using this assay, we can distinguish variants that cause XLRP, CSNB, and nondisease-causing polymorphisms. Furthermore, we also developed an assay based on the cilia localization of the *RPGR*¹⁻¹⁹ isoform to distinguish among variants that cause XLRP, which disrupt cilia localization, and CSNB or nondisease-causing polymorphisms, which have normal cilia localization of the *RPGR*¹⁻¹⁹ isoform. These methods provide a cost-effective test for *RPGR* functional mutation analysis.

The existence of multiple isoforms in cells and tissues makes the study of *RPGR* function challenging. While the *RPGR*^{ORF15} isoform is mainly expressed in the retina, the *RPGR*¹⁻¹⁹ isoform has a broader expression pattern (12, 16, 46). The shared N-terminal RLD region suggests that these isoforms have some functions in common, whereas the unique C termini of these isoforms suggest each isoform may also have different functional properties. Several lines of evidence support this hypothesis. First, the *RPGR*¹⁻¹⁹ isoform, which has a C-terminal prenylation site, localizes to primary cilia both in human RPE1 cells and mouse IMCD3 cells (17, 27, 41). In contrast, the *RPGR*^{ORF15} isoform does not localize to cilia in cultured cells. Second, rescue experiments in *Rpgr* knockout mice demonstrated that the *RPGR*^{ORF15} isoform, but not the *RPGR*¹⁻¹⁹ isoform, is the functionally significant isoform in photoreceptor cells (13, 14, 47). Third, some *RPGR* patients have other phenotypes including respiratory tract infections, hearing loss, and primary ciliary dyskinesia in addition to XLRP (15, 46, 48). Given the broader expression of the *RPGR*¹⁻¹⁹ isoform, this might reflect the function of *RPGR*¹⁻¹⁹ in nonretinal tissues.

The functional importance of *RPGR* isoforms in the retina is not fully understood. It has been shown that the level of the *RPGR*¹⁻¹⁹ isoform is gradually decreased while the level of the *RPGR*^{ORF15} isoform is gradually increased during eye development, implying the *RPGR*¹⁻¹⁹ isoform plays a role during the early stage of eye development, while the *RPGR*^{ORF15} isoform has an important function in the mature retina (14). The fact that both *RPGR* isoforms interact with the same endogenous interactors suggests that they may compete with each other for the availability of endogenous binding partners, therefore fine tuning each isoforms' function. Consistent with this notion, truncated *RPGR* has been shown to have dominant effects on endogenous *RPGR* proteins (39, 49). This may explain why overexpression of the *RPGR*¹⁻¹⁹ isoform in mice causes retinal degeneration.

The discrepancy between our data and published data regarding the effect of *RPGR* on INPP5E ciliary localization may be due to species and cell-type differences. We used human RPE1 cells in our study, while data in the literature was generated using mouse fibroblast cells (27). Another possibility is the existence of modifying genes, which, in combination with loss of *RPGR*, regulates INPP5E ciliary localization. When we generate stable *RPGR* knockout cell lines in RPE1 cells using CRISPR-Cas9, we selected two gRNAs targeting *RPGR*. Ten stable cell lines from one guide all show ciliary localization of INPP5E. Interestingly, four of eight stable cell lines generated using a second guide show the lack of ciliary localization of INPP5E, suggesting there may be genes whose functions are disturbed by the guide. Interestingly, it has been shown that variations in *RPGRIP1L* and *NPHP5* serve as modifiers for *RPGR* (32).

Although our *in vitro* assay raises questions about the nature of some known *RPGR* missense variations, we cannot completely rule out the possibility that these missense variations are causative mutations. These missense variations could affect the

protein stability of *RPGR*. We cannot distinguish this possibility with our assay.

Materials and Methods

Study Approval. All experiments involving human skin biopsy specimens were conducted with the approval of and under the supervision of the University of Iowa's Internal Review Board (IRB, application no. 200202022).

Reagents and Antibodies. The following antibodies were used in this study: *RPGR* rabbit polyclonal antibody (HPA001593, 1:200 for IF; Sigma), mouse monoclonal anti-polyglutamylated tubulin [clone GT335, AG-20B-0020, 1:1,000 for immunofluorescence (IF), 1:1,000 for Western blot (WB); AdipoGen], *PDE6D* rabbit polyclonal antibody (MBS7005086, 1:1,000 for WB; MyBiosources), *INPP5E* rabbit polyclonal antibody (17797-1-AP, 1:500 for IF, 1:500 for WB; Proteintech), *RPGRIP1L* rabbit polyclonal antibody (55160-1-AP, 1:300 for IF, 1:500 for WB; Proteintech), *RPGRIP1L* rabbit polyclonal antibody (HPA039405, 1:300 for WB; Sigma), *ARL13B* mouse monoclonal antibody (N295B/66, 1:500 for IF; NeuroMab), FLAG mouse monoclonal antibody (F1804, 1:200 for IF; Sigma), HRP-conjugated FLAG mouse monoclonal antibody (A8592, 1:20,000 for WB; Sigma), *GAPDH* mouse monoclonal antibody (MA5-15738, 1:10,000 for WB; Invitrogen), and GFP rabbit monoclonal antibody (G10362, 1:500 for IF; Invitrogen). Blasticidin was from InvivoGen. SMARTpool siRNA against human *RPGR* and *INPP5E* were from Dharmacon.

Cell Cultures. hTERT-RPE1 cells and mouse IMCD3 cells were maintained in DMEM/F12 (Invitrogen) with 10% FBS (Gibco) and penicillin/streptomycin. Human HEK293T cells were maintained in DMEM (Invitrogen) with 10% FBS and penicillin/streptomycin. Skin fibroblasts were maintained in MEM alpha (Invitrogen) with 10% FBS and primocin (InvivoGen).

Generation of RPE1 Knockout Cell Lines Using CRISPR-Cas9. We generated *RPGR*, *PDE6D*, *INPP5E*, and *RPGRIP1L* knockout cell lines in RPE1 cells using CRISPR-Cas9. The guide sequences for *RPGR* is as follows: guide 1 GAAGT-GAAATTAGTGCCTG. Guide 2 GTCCCTGTACATCTTTCATG. The guide sequence for *PDE6D* is as follows: GGACCTGTCTGTCCCTGGTG. The guide sequence for *INPP5E* is as follows: GAGGGTTACCCCGAGGAC. The guide sequence for *RPGRIP1L* is as follows: GGTGTCACGTGTGTCAGTCGTG. Stable clones were selected with blasticidine and indels were identified by Sanger sequencing. Stable clones were also verified by immunofluorescent staining or Western blotting whenever antibodies were available.

Generation of Human *RPGR* Missense Variations and *RPGR* Shared Region. *RPGR* missense variations were generated by site-directed mutagenesis (Stratagene) using N-terminal Flag-S-tagged or GFP-S-tagged wild-type *RPGR* as template and mutations were verified by Sanger sequencing. *RPGR* shared region was generated by PCR and verified by Sanger sequencing.

Immunoprecipitation. *RPGR* WT and missense variations were transfected into HEK293T cells in a six-well plate. Forty-eight hours after transfection, the cells were lysed in lysis buffer (1× PBS, 1% Triton X-100, and protease inhibitor; Roche) and spun at 20,000 × g for 15 min at 4 °C. Cleared lysates were incubated with anti-Flag beads (Biotool) for 4 h. The beads were washed four times with lysis buffer, and the interactions were detected by Western blotting.

Immunofluorescence Microscopy. Cells were fixed in 4% paraformaldehyde in PBS for 10 min and permeabilized with 0.2% Triton X-100 at room temperature for 7 min or fixed with cold methanol for 5 min (for γ -tubulin stain). Cells were washed three times with PBS and blocked with blocking buffer (1% BSA in PBS). Primary antibodies were diluted in blocking buffer and incubated at room temperature for 1 h. Cells were washed 3× PBS, blocked with blocking buffer, then incubated with Alexa 488- or Alexa 568-labeled secondary antibodies (1:1,500 for IF; Invitrogen). Slides were mounted with VectaShield mounting medium with DAPI (Vector Laboratories).

Image Quantification and Statistical Analysis. To quantify GFP⁺ cilia in GFP-tagged *RPGR* WT and mutant-transfected RPE1 cells and IMCD3 cells, 10–15 random fields (10 fields for IMCD3 cells and 12–15 fields for RPE1 cells) under 60× objective were chosen to count GFP⁺ cilia and DAPI to count for total cells. To quantify cilia number frequency, 5–10 random fields (10 fields for *RPGRIP1L* knockout cells, 5 fields for the rest gene knockout cells) under 60× objective were chosen to count cilia number and DAPI to count for total cells. To quantify *RPGRIP1L* stain, 10 random pictures were taken under 100× objective, anti-polyglutamylated tubulin was used to count cilia, and γ -tubulin was used to count basal body. To quantify *RPGR* and

INPP5E frequency, about 100 cells under 100 $\times$ objective were counted and anti-polyglutamylated tubulin was used to count cilia. For Western blots quantification, images were quantified using NIH ImageJ. We performed statistical analysis using unpaired *t* tests. Mean values $\pm$ SEM are reported.

ACKNOWLEDGMENTS. We thank the patients and family members for their willingness to participate in this study. This work is supported by NIH Grants EY-011298, EY-017168 (to V.C.S.), R01-EY026008 (to B.A.T.), and R01-EY026008 (to E.M.S.).

- Fahim AT, Daiger SP, Weleber RG (1993–2018) Nonsyndromic retinitis pigmentosa overview. *GeneReviews*, eds Adam MP, et al. (University of Washington, Seattle).
- Mockel A, et al. (2011) Retinal dystrophy in Bardet-Biedl syndrome and related syndromic ciliopathies. *Prog Retin Eye Res* 30:258–274.
- Rosenberg T, Haim M, Hauch AM, Parving A (1997) The prevalence of Usher syndrome and other retinal dystrophy-hearing impairment associations. *Clin Genet* 51:314–321.
- Williams DS (2008) Usher syndrome: Animal models, retinal function of Usher proteins, and prospects for gene therapy. *Vision Res* 48:433–441.
- Andréasson S, et al. (1997) Phenotypes in three Swedish families with X-linked retinitis pigmentosa caused by different mutations in the RPGR gene. *Am J Ophthalmol* 124:95–102.
- Churchill JD, et al. (2013) Mutations in the X-linked retinitis pigmentosa genes RPGR and RP2 found in 8.5% of families with a provisional diagnosis of autosomal dominant retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 54:1411–1416.
- Daiger SP, Bowne SJ, Sullivan LS (2014) Genes and mutations causing autosomal dominant retinitis pigmentosa. *Cold Spring Harb Perspect Med* 5:a017129.
- Ge Z, et al. (2015) NGS-based molecular diagnosis of 105 eyeGENE(®) probands with retinitis pigmentosa. *Sci Rep* 5:18287.
- Kajiwa K, Berson EL, Dryja TP (1994) Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. *Science* 264:1604–1608.
- Stone EM, et al. (2017) Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. *Ophthalmology* 124:1314–1331.
- He S, et al. (2008) Retinitis pigmentosa GTPase regulator (RPGR) protein isoforms in mammalian retina: Insights into X-linked retinitis pigmentosa and associated ciliopathies. *Vision Res* 48:366–376.
- Kirschner R, et al. (1999) RPGR transcription studies in mouse and human tissues reveal a retina-specific isoform that is disrupted in a patient with X-linked retinitis pigmentosa. *Hum Mol Genet* 8:1571–1578.
- Hong DH, Pawlyk BS, Adamian M, Sandberg MA, Li T (2005) A single, abbreviated RPGR-ORF15 variant reconstitutes RPGR function in vivo. *Invest Ophthalmol Vis Sci* 46:435–441.
- Wright RN, Hong DH, Perkins B (2011) Misexpression of the constitutive Rprgr(ex1-19) variant leads to severe photoreceptor degeneration. *Invest Ophthalmol Vis Sci* 52:5189–5201.
- Bukowy-Bieryłło Z, et al. (2013) RPGR mutations might cause reduced orientation of respiratory cilia. *Pediatr Pulmonol* 48:352–363.
- Hong DH, et al. (2003) RPGR isoforms in photoreceptor connecting cilia and the transitional zone of motile cilia. *Invest Ophthalmol Vis Sci* 44:2413–2421.
- Lee JJ, Seo S (2015) PDE6D binds to the C-terminus of RPGR in a prenylation-dependent manner. *EMBO Rep* 16:1581–1582.
- Patil SB, Verma R, Venkatareddy M, Khanna H (2010) Expression and localization of the ciliary disease protein retinitis pigmentosa GTPase regulator in mammalian kidney. *Kidney Int* 78:622–623.
- Gakovic M, et al. (2011) The role of RPGR in cilia formation and actin stability. *Hum Mol Genet* 20:4840–4850.
- Megaw R, et al. (2017) Gelsolin dysfunction causes photoreceptor loss in induced pluripotent cell and animal retinitis pigmentosa models. *Nat Commun* 8:271.
- Murga-Zamalloa CA, Swaroop A, Khanna H (2009) RPGR-containing protein complexes in syndromic and non-syndromic retinal degeneration due to ciliary dysfunction. *J Genet* 88:399–407.
- Rachel RA, Li T, Swaroop A (2012) Photoreceptor sensory cilia and ciliopathies: Focus on CEP290, RPGR and their interacting proteins. *Cilia* 1:22.
- Rao KN, et al. (2016) Loss of human disease protein retinitis pigmentosa GTPase regulator (RPGR) differentially affects rod or cone-enriched retina. *Hum Mol Genet* 25:1345–1356.
- Wright RN, Hong DH, Perkins B (2012) RprgrORF15 connects to the usher protein network through direct interactions with multiple whirlin isoforms. *Invest Ophthalmol Vis Sci* 53:1519–1529.
- Murga-Zamalloa CA, Atkins SJ, Peranen J, Swaroop A, Khanna H (2010) Interaction of retinitis pigmentosa GTPase regulator (RPGR) with RAB8A GTPase: Implications for cilia dysfunction and photoreceptor degeneration. *Hum Mol Genet* 19:3591–3598.
- Otto EA, et al. (2005) Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. *Nat Genet* 37:282–288.
- Rao KN, Zhang W, Li L, Anand M, Khanna H (2016) Prenylated retinal ciliopathy protein RPGR interacts with PDE6 δ and regulates ciliary localization of Joubert syndrome-associated protein INPP5E. *Hum Mol Genet* 25:4533–4545.
- Roepman R, et al. (2000) The retinitis pigmentosa GTPase regulator (RPGR) interacts with novel transport-like proteins in the outer segments of rod photoreceptors. *Hum Mol Genet* 9:2095–2105.
- Roepman R, Wolfgram U (2007) Protein networks and complexes in photoreceptor cilia. *Subcell Biochem* 43:209–235.
- Shu X, et al. (2005) RPGR ORF15 isoform co-localizes with RPRIP1 at centrioles and basal bodies and interacts with nucleophosmin. *Hum Mol Genet* 14:1183–1197.
- Wätzlich D, et al. (2013) The interplay between RPGR, PDE6 and Arl2/3 regulate the ciliary targeting of farnesylated cargo. *EMBO Rep* 14:465–472.
- Fahim AT, et al. (2012) Polymorphic variation of RPRIP1L and IQCB1 as modifiers of X-linked retinitis pigmentosa caused by mutations in RPGR. *Adv Exp Med Biol* 723:313–320.
- Khanna H, et al. (2005) RPGR-ORF15, which is mutated in retinitis pigmentosa, associates with SMC1, SMC3, and microtubule transport proteins. *J Biol Chem* 280:33580–33587.
- Chang B, et al. (2006) In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse. *Hum Mol Genet* 15:1847–1857.
- Breuer DK, et al. (2002) A comprehensive mutation analysis of RP2 and RPGR in a North American cohort of families with X-linked retinitis pigmentosa. *Am J Hum Genet* 70:1545–1554.
- Buraczynska M, et al. (1997) Spectrum of mutations in the RPGR gene that are identified in 20% of families with X-linked retinitis pigmentosa. *Am J Hum Genet* 61:1287–1292.
- Fujita R, et al. (1997) Analysis of the RPGR gene in 11 pedigrees with the retinitis pigmentosa type 3 genotype: Paucity of mutations in the coding region but splice defects in two families. *Am J Hum Genet* 61:571–580.
- Guevara-Fujita M, et al. (2001) Five novel RPGR mutations in families with X-linked retinitis pigmentosa. *Hum Mutat* 17:151.
- Hong DH, Pawlyk BS, Adamian M, Li T (2004) Dominant, gain-of-function mutant produced by truncation of RPGR. *Invest Ophthalmol Vis Sci* 45:36–41.
- Shu X, et al. (2007) RPGR mutation analysis and disease: An update. *Hum Mutat* 28:322–328.
- Fansa EK, O'Reilly NJ, Ismail S, Wittinghofer A (2015) The N- and C-terminal ends of RPGR can bind to PDE6 δ . *EMBO Rep* 16:1583–1585.
- Baehr W (2014) Membrane protein transport in photoreceptors: The function of PDE6: The Proctor lecture. *Invest Ophthalmol Vis Sci* 55:8653–8666.
- Sharon D, et al. (2000) X-linked retinitis pigmentosa: Mutation spectrum of the RPGR and RP2 genes and correlation with visual function. *Invest Ophthalmol Vis Sci* 41:2712–2721.
- Shu X, McDowall E, Brown AF, Wright AF (2008) The human retinitis pigmentosa GTPase regulator gene variant database. *Hum Mutat* 29:605–608.
- Linari M, et al. (1999) The retinitis pigmentosa GTPase regulator, RPGR, interacts with the delta subunit of rod cyclic GMP phosphodiesterase. *Proc Natl Acad Sci USA* 96:1315–1320.
- Iannaccone A, et al. (2004) Increasing evidence for syndromic phenotypes associated with RPGR mutations. *Am J Ophthalmol* 137:785–786, author reply 786.
- Pawlyk BS, et al. (2016) Photoreceptor rescue by an abbreviated human RPGR gene in a murine model of X-linked retinitis pigmentosa. *Gene Ther* 23:196–204.
- Iannaccone A, et al. (2003) Clinical and immunohistochemical evidence for an X-linked retinitis pigmentosa syndrome with recurrent infections and hearing loss in association with an RPGR mutation. *J Med Genet* 40:e118.
- Rozet JM, et al. (2002) Dominant X-linked retinitis pigmentosa is frequently accounted for by truncating mutations in exon ORF15 of the RPGR gene. *J Med Genet* 39:284–285.